1
Clinical Trials associated with MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells(H. Lee Moffitt Cancer Center & Research Institute)A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms.
The purpose of this study is to find out what side effects are caused in this study and whether Fludarabine with the dendritic cell vaccine (DC vaccine) can increase the ability of the immune system to recognize melanoma.
100 Clinical Results associated with MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells(H. Lee Moffitt Cancer Center & Research Institute)
100 Translational Medicine associated with MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells(H. Lee Moffitt Cancer Center & Research Institute)
100 Patents (Medical) associated with MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells(H. Lee Moffitt Cancer Center & Research Institute)
100 Deals associated with MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells(H. Lee Moffitt Cancer Center & Research Institute)